HealthQuill USFDA
A machine developed by US-based HistoSonics Inc. to treat patients with primary and secondary liver tumours and other hard-to-reach tumours will be installed at the UKā€™s Cambridge University Hospitals later this year.
Drugs Health Pharma

UK patients to be first to get non-invasive liver cancer treatment in Europe

HQ Team June 12, 2025: A machine developed by US-based HistoSonics Inc. to treat patients with primary and secondary liver tumours and other.

Read More
GSK Plc. and Spero Therapeutics have stopped their combined trial of an investigational oral treatment for urinary tract infections after the study achieved its goal on efficacy.
Drugs Health Pharma

GSK, Sepro end trial for oral drug to treat urinary tract infections

Ā HQ Team May 28, 2025: GSK Plc. and Spero Therapeutics have stopped their combined trial of an investigational oral treatment for urinary tract.

Read More
The US Food and Drug Administration has granted marketing access to Fujirebio Diagnostics, Inc.ā€™s blood test to diagnose Alzheimerā€™s disease, the first such approval in the country.
Drugs Health Pharma

Simple blood test to detect Alzheimerā€™s disease gets US regulator’s nod

HQ Team May 18, 2025: The US Food and Drug Administration has granted marketing access to Fujirebio Diagnostics, Inc.ā€™s blood test to diagnose.

Read More
The US Food and Drug Administration has approved Britainā€™s GSK Plcā€™s drug to treat urinary tract infections in adult women and girls above 12 years, according to the company.
Drugs Medical Pharma

GSKā€™s drug to fight urinary tract infections gets USFDA approval

HQ Team March 26, 2025: The US Food and Drug Administration has approved Britainā€™s GSK Plcā€™s drug to treat urinary tract infections in.

Read More
Eli Lilly cuts price of weight-loss drug Zepbound to take on copycats
Drugs Health Pharma

Eli Lilly cuts price of weight-loss drug Zepbound to take on copycats

Eli Lilly and CompanyĀ cut the prices of its weight-loss drugĀ  Zepbound, available in single-dose vials, in a bid to end compounding companies from.

Read More
Regeneron Pharmaceuticals, Inc.ā€™s investigational gene therapy improved hearing in 10 out of 11 children born with hearing loss because of gene mutation, according to a company statement.
Drugs Health Medical

Regeneronā€™s trial therapy improves hearing in children with gene mutations

Regeneron Pharmaceuticals, Inc.ā€™s investigational gene therapy improved hearing in 10 out of 11 children born with hearing loss because of gene mutation, according.

Read More
Irelandā€™s Medtronic Plcā€™s deep brain stimulation device for patients with Parkinsonā€™s disease has been approved by the US Food and Drug Administration, according to a company statement.
Health Medical Pharma

Medtronic Plc’s neurostimulator for Parkinson’s gets USFDA approval

Irelandā€™s Medtronic Plcā€™s deep brain stimulation device for patients with Parkinsonā€™s disease has been approved by the US Food and Drug Administration, according.

Read More
FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing the Anglo-Swedish firm to gain access to an anaemia drug in the worldā€™s most populated nation.
Drugs Health Pharma

AstraZeneca Plc buys China unit of FibroGen Inc for $160 million

HQ Team February 21, 2025: FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing.

Read More
Merck & Co. halted its final-phase study of its experimental drug for pulmonary arterial hypertension after previous studies proved its ā€œrobust efficacy,ā€ according to a company statement.
Drugs Health Medical

Merck & Co stops final-stage drug trial for treating PAH

Merck & Co. halted its final-phase study of its experimental drug for pulmonary arterial hypertension after previous studies proved its ā€œrobust efficacy,ā€ according.

Read More
The US drug regulator has put a clinical hold on Atara Biotherapeuticsā€™ T-cell therapies for cancer and autoimmune diseases after issues were observed at a third-party manufacturing facility.
Drugs Health Medical Pharma

FDA places Atara’s Biothearapeutics’ cancer, autoimmune therapies on hold

The US drug regulator has put a clinical hold on Atara Biotherapeuticsā€™ T-cell therapies for cancer and autoimmune diseases after issues were observed.

Read More